A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(15 sites)

China

Fujian Cancer Hospital, Fuzhou, Fujian

Dongguan People's Hospital, Dongguan, Guangdong

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong

The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong

Zhongshan City People's Hospital, Guangzhou, Guangdong

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen, Shenzhen, Guangdong

Guangxi Medical University Cancer Hospital, Nanning, Guangxi

Guizhou Medical University Cancer Hospital, Guiyang, Guizhou

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei

Xiangya Hospital of Central South University, Changsha, Hunan

First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi

Sichuan Cancer Hospital, Chengdu, Sichuan

West China Hospital of Sichuan University, Chengdu, Sichuan

Zhejiang Cancer Hospital, Hangzhou, Zhejiang